Adenoviral vectors transduce alveolar macrophages in lung cancer models

Authors:

Abstract
Adenoviral vectors expressing Cre recombinase are commonly used to initiate tumor formation in murine lung cancer models. While these vectors are designed to target genetic recombination to lung epithelial cells, adenoviruses can infect additional cell types that potentially influence tumor development. Our goal was to explore the consequences of adenoviral-mediated alveolar macrophage (AM) transduction in a Kras-initiated lung tumor model. As expected, treatment of animals harboring the KrasLSL-G12D allele and an inducible green fluorescence protein (GFP) tracking allele with an adenoviral vector expressing Cre recombinase under the control of the cytomegalovirus (CMV) promoter (Ad5-CMV-Cre), caused GFP-positive lung adenocarcinomas. Surprisingly, however, up to 70% of the total GFP+ cells were AM, and GFP+ AM could be detected 6 months after tumor initiation, and transduced AM demonstrated Kras activation and increased proliferation. In contrast, recombination was not detected in other immune cell populations and AM recombination could be eliminated by tumor initiation with an adenovirus expressing Cre recombinase under the control of the surfactant protein C (SPC) promoter. In addition, AM isolated from KrasLSL-G12D animals and transduced by Ad5-CMV-Cre ex vivo displayed prolonged survival in vitro and increased the growth of murine lung adenocarcinoma CMT/167 cells when co-injected in an orthotopic flank model. Given the importance of the immune system in tumor development and progression, inadvertent AM transduction by Ad5-CMV-Cre merits careful consideration during lung cancer model selection particularly if studies evaluating the tumor-immune interactions are planned.
Funding Information
  • HHS | NIH | National Cancer Institute (T32 CA174648)
  • HHS | NIH | National Cancer Institute (P30 CA046934)
  • HHS | NIH | National Cancer Institute (P30 CA046934)
  • HHS | NIH | National Cancer Institute (R21 CA194662)
  • HHS | NIH | National Cancer Institute (P50 CA058187)
  • HHS | NIH | National Cancer Institute (R01 CA162226)
  • HHS | NIH | National Cancer Institute
  • HHS | NIH | National Cancer Institute
  • HHS | NIH | National Cancer Institute
  • U.S. Department of Veterans Affairs (IK2BX001282)
  • HHS | NIH | National Cancer Institute (T32 CA17468)
  • HHS | NIH | National Cancer Institute (T32 AG000279)
  • HHS | NIH | National Cancer Institute (R01 CA157850)
  • HHS | NIH | National Cancer Institute (P50 CA058187)

This publication has 41 references indexed in Scilit: